News Related to MDM2 Inhibitor

Related coverage linked through entity extraction aliases.

International Workshops Prioritize Drug Targets for Childhood Medulloblastoma and Rhabdoid Tumours

Jul 13, 2026

International expert workshops have identified priority therapeutic targets for medulloblastoma and rhabdoid tumours, two rare childhood cancers. For medulloblastoma, key priorities include SRC degradation, c-MYC/MYCN inhibition, and B7-H3 targeted approaches. For rhabdoid tumours, DCAF5 and MDM2 were highlighted, with EZH2 degraders showing potential.

$3.2 million project targets MDM2 in triple-negative breast cancer

Apr 23, 2026

A $3.2 million research collaboration is developing a drug that directly breaks down MDM2 in triple-negative breast cancer. Early laboratory models showed tumour shrinkage, and the team is studying dosing, safety and performance.